$ENGN

$1.58 +$0.02 (1.28%) Close

$ENGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 67.0M shares outstanding

Who owns ENGN?

By type of holder

Institutions 74.6% Insiders 10.2% Everyone else 15.2%

Concentration Top 10 holders own 56.5%

FCPM III Services B.V. 14.4% · BML Capital Management, LLC 10.0%

Institutional ownership

74.6%

-9.3 pts vs last qtr

Institutional holders

-3 vs last qtr

Net shares bought

−6.3M

by institutions in Q2 2026

New / sold out

20 / 23

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

BML Capital Management, LLC NEW +6.7M
Ameriprise Financial Inc NEW +2.7M

Biggest sellers in Q2 2026

Venrock Adviser, LLC SOLD OUT −4.8M
Blue Owl Capital Holdings LP SOLD OUT −4.4M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for enGene Therapeutics Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2022–FY2025

+7702.7%

+327.31% a year

Each share's claim on the business

−98.7%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $18.5M

over 4 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years32% Under 1 year68%

Quarterly turnover

39.4%

of institutional shares changed hands

Top 10 managers, median time held

2 quarters

Super Investors

Investment managers reporting ENGN on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
FI FCPM III Services B.V.	9.6M	14.37%	Unchanged	2023	2.2%
Shares held by quarter Peak holding9.6M (Q4'24) Change over 8 quarters+954.6K Share of the company14.370% FCPM III Services B.V.'s full portfolio →
BC BML Capital Management, LLC	6.7M	9.95%	NEW	Q2 '26	6.6%
Shares held by quarter Peak holding6.7M (Q2'26) Change over 8 quarters+6.7M Share of the company9.950% BML Capital Management, LLC's full portfolio →

FCPM III Services B.V.

9.6M

% of company

14.37%

Change vs last qtr

Unchanged

Held since

2023

BML Capital Management, LLC

6.7M

% of company

9.95%

Change vs last qtr

NEW

Held since

Q2 '26

28 more super investors behind a free account

See every manager holding enGene Therapeutics Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ENGN on Form N-PORT; together they hold 2.7% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
EH Eventide Healthcare & Life Sciences Fund Mutual Fund Series Trust	$8.58M	950.0K	1.42%	0.51%	December 31, 2025
FB Franklin Biotechnology Discovery Fund Franklin Strategic Series	$3.54M	486.6K	0.73%	0.34%	April 30, 2026

Eventide Healthcare & Life Sciences Fund

Mutual Fund Series Trust

Position value

$8.58M

% of company

1.42%

% of the fund

0.51%

As of

December 31, 2025

Franklin Biotechnology Discovery Fund

Franklin Strategic Series

Position value

$3.54M

% of company

0.73%

% of the fund

0.34%

As of

April 30, 2026

11 more funds behind a free account

See every fund holding enGene Therapeutics Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
AP Astley-Sparke Philip Insider	20.0K	0.03%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.030% Astley-Sparke Philip's insider activity →
BM Boyd Matthew Ross Insider	7.5K	0.01%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.010% Boyd Matthew Ross's insider activity →

Astley-Sparke Philip

Insider

20.0K

% of company

0.03%

Change vs last qtr

—

Held since

—

Boyd Matthew Ross

Insider

7.5K

% of company

0.01%

Change vs last qtr

—

Held since

—

2 more holders behind a free account

See every insider and 5%+ holder of enGene Therapeutics Inc..

Comments